The Food and Drug Administration approved pembrolizumab, or Keytruda, from Merck with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 6/7/2024
- Coherus Biosciences appoints Karachun to board of directors
- Merus price target raised to $91 from $84 at BMO Capital
- Moderna, Merck announce 3-year data for mRNA-4157 in combination with Keytruda